getting off tirzepatide Compounding pharmacies can resume making as FDA reconsiders shortage There may not be a

Considerations for using induction therapy may include: (1) high sensitization of the patient (2) younger patients or multiparous women with theoretically more robust immune systems (3) crossing of recipient antibodies with donor antigens (3) renal function to provide a CNI sparing regimen long term Some considerations for avoiding induction may include: (1) older age of the recipient (2) underlying comorbid conditions such as infections or frailty of the recipient What are expected activity restrictions post-transplant

Important safety considerations include: Separate fiber supplements from medications : Take fiber supplements at least 2 hours apart from oral medications to avoid potential interference with absorption Monitor for obstruction symptoms : Severe abdominal pain, inability to pass gas, or vomiting requires immediate medical evaluation, as FDA labels for GLP-1 medications include rare postmarketing reports of intestinal obstruction (ileus) [1] [2] Coordinate with healthcare providers : Patients with inflammatory bowel disease, diverticulitis history, or other gastrointestinal conditions need individualized fiber recommendations Adjust fluid intake appropriately : Follow medical guidance if you have conditions requiring fluid restriction Patients should contact their healthcare provider if gastrointestinal symptoms persist despite dietary modifications, worsen significantly, or include warning signs such as blood in stool, unintentional weight loss beyond expected therapeutic effects, or severe abdominal pain

Patients may review the current compounded GLP-1 options on the official MEDVi website and complete an evaluation to determine eligibility

Then, about eight months ago, things heated up